Market closedNon-fractional
Chimerix/CMRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Chimerix
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Ticker
CMRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Durham, United States
Employees
72
Website
www.chimerix.com
Chimerix Metrics
BasicAdvanced
$75M
Market cap
-
P/E ratio
-$0.93
EPS
1.19
Beta
-
Dividend rate
Price and volume
Market cap
$75M
Beta
1.19
Financial strength
Current ratio
8.61
Quick ratio
8.399
Long term debt to equity
0.577
Total debt to equity
0.577
Management effectiveness
Return on assets (TTM)
-26.30%
Return on equity (TTM)
-39.86%
Valuation
Price to revenue (TTM)
1,811.28
Price to book
0.43
Price to tangible book (TTM)
0.43
Price to free cash flow (TTM)
-1.151
Growth
Revenue change (TTM)
-99.88%
Earnings per share change (TTM)
-147.33%
3-year revenue growth
-80.54%
3-year earnings per share growth
-21.84%
What the Analysts think about Chimerix
Analyst Ratings
Majority rating from 7 analysts.
Chimerix Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$22M
20.44%
Profit margin
0.00%
NaN%
Chimerix Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.21
-$0.27
-$0.20
-$0.25
-
Expected
-$0.24
-$0.23
-$0.24
-$0.22
-$0.24
Surprise
-13.78%
17.98%
-15.20%
13.86%
-
Chimerix News
AllArticlesVideos
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·23 hours ago
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Chimerix stock?
Chimerix (CMRX) has a market cap of $75M as of July 06, 2024.
What is the P/E ratio for Chimerix stock?
The price to earnings (P/E) ratio for Chimerix (CMRX) stock is 0 as of July 06, 2024.
Does Chimerix stock pay dividends?
No, Chimerix (CMRX) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Chimerix dividend payment date?
Chimerix (CMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Chimerix?
Chimerix (CMRX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Chimerix stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.